JPS63174934A - ウロキナ−ゼ前駆体乾燥製剤 - Google Patents
ウロキナ−ゼ前駆体乾燥製剤Info
- Publication number
- JPS63174934A JPS63174934A JP62004178A JP417887A JPS63174934A JP S63174934 A JPS63174934 A JP S63174934A JP 62004178 A JP62004178 A JP 62004178A JP 417887 A JP417887 A JP 417887A JP S63174934 A JPS63174934 A JP S63174934A
- Authority
- JP
- Japan
- Prior art keywords
- precursor
- gelatin
- dry preparation
- urokinase
- urokinase precursor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002243 precursor Substances 0.000 title claims description 39
- 238000002360 preparation method Methods 0.000 title claims description 10
- 229960005356 urokinase Drugs 0.000 title claims description 8
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 title claims description 7
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 title claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 12
- 239000008273 gelatin Substances 0.000 claims description 12
- 229920000159 gelatin Polymers 0.000 claims description 12
- 235000019322 gelatine Nutrition 0.000 claims description 12
- 235000011852 gelatine desserts Nutrition 0.000 claims description 12
- 239000003381 stabilizer Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 229940012957 plasmin Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- -1 organic acid salts Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- FWDLHTBMGQEUDU-UHFFFAOYSA-M sodium;2-hydroxy-2-phenylacetate Chemical compound [Na+].[O-]C(=O)C(O)C1=CC=CC=C1 FWDLHTBMGQEUDU-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62004178A JPS63174934A (ja) | 1987-01-13 | 1987-01-13 | ウロキナ−ゼ前駆体乾燥製剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62004178A JPS63174934A (ja) | 1987-01-13 | 1987-01-13 | ウロキナ−ゼ前駆体乾燥製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63174934A true JPS63174934A (ja) | 1988-07-19 |
| JPH0480010B2 JPH0480010B2 (enrdf_load_stackoverflow) | 1992-12-17 |
Family
ID=11577455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62004178A Granted JPS63174934A (ja) | 1987-01-13 | 1987-01-13 | ウロキナ−ゼ前駆体乾燥製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63174934A (enrdf_load_stackoverflow) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996011264A1 (fr) * | 1994-10-11 | 1996-04-18 | Ajinomoto Co., Inc. | Transglutaminase stabilisee et preparation enzymatique contenant cette transglutaminase |
| JP2007501223A (ja) * | 2003-08-05 | 2007-01-25 | フジ フォト フィルム ビー．ブイ． | 安定剤としての組換え又は合成ゼラチンのワクチン中の使用 |
| WO2012064369A1 (en) * | 2010-11-10 | 2012-05-18 | Tengion, Inc. | Injectable formulations for organ augmentation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5668607A (en) * | 1979-11-07 | 1981-06-09 | Teikoku Hormone Mfg Co Ltd | Medical preparation with storage stability |
| JPS61238731A (ja) * | 1985-04-16 | 1986-10-24 | Green Cross Corp:The | ウロキナーゼ前駆体乾燥製剤 |
| JPS61238732A (ja) * | 1985-04-16 | 1986-10-24 | Green Cross Corp:The | ウロキナーゼ前駆体乾燥製剤 |
-
1987
- 1987-01-13 JP JP62004178A patent/JPS63174934A/ja active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5668607A (en) * | 1979-11-07 | 1981-06-09 | Teikoku Hormone Mfg Co Ltd | Medical preparation with storage stability |
| JPS61238731A (ja) * | 1985-04-16 | 1986-10-24 | Green Cross Corp:The | ウロキナーゼ前駆体乾燥製剤 |
| JPS61238732A (ja) * | 1985-04-16 | 1986-10-24 | Green Cross Corp:The | ウロキナーゼ前駆体乾燥製剤 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996011264A1 (fr) * | 1994-10-11 | 1996-04-18 | Ajinomoto Co., Inc. | Transglutaminase stabilisee et preparation enzymatique contenant cette transglutaminase |
| JP3651003B2 (ja) * | 1994-10-11 | 2005-05-25 | 味の素株式会社 | 安定化されたトランスグルタミナーゼ及びそれを含む酵素製剤 |
| JP2007501223A (ja) * | 2003-08-05 | 2007-01-25 | フジ フォト フィルム ビー．ブイ． | 安定剤としての組換え又は合成ゼラチンのワクチン中の使用 |
| WO2012064369A1 (en) * | 2010-11-10 | 2012-05-18 | Tengion, Inc. | Injectable formulations for organ augmentation |
| CN103298498A (zh) * | 2010-11-10 | 2013-09-11 | 坦吉恩股份有限公司 | 用于器官增强的注射制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0480010B2 (enrdf_load_stackoverflow) | 1992-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4505893A (en) | Purified plasminogen activator, process for its production and thrombolytic composition containing it | |
| US4568544A (en) | Aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method | |
| US4552760A (en) | Method for stabilizing tissue plasminogen activator and a stable aqueous solution or powder containing the same | |
| CA1340270C (en) | Thrombolytic composition and a process for production thereof | |
| HU185223B (en) | Process for preparing an enzymatic derivative containing a binary complex of streptokynase and plasminogen | |
| US4996050A (en) | Fibrinolytic activity enhancer | |
| JPH02268681A (ja) | ウロキナーゼ前駆体の安定化方法及び乾燥製剤 | |
| CA1336585C (en) | Method of stabilizing urokinase precursor and dry preparation containing said precursor | |
| US5075230A (en) | Stabilized plasminogen activator precursor and method of producing the same | |
| Maksimenko et al. | Water-soluble urokinase derivatives with increased affinity to the fibrin clot | |
| JPS63174934A (ja) | ウロキナ−ゼ前駆体乾燥製剤 | |
| JPH0462302B2 (enrdf_load_stackoverflow) | ||
| EP0139447A2 (en) | A process for preparing urokinase zymogen | |
| EP0151996B1 (en) | Process for the preparation of a double-chain plasminogen activator | |
| JPH0462301B2 (enrdf_load_stackoverflow) | ||
| JPH0569507B2 (enrdf_load_stackoverflow) | ||
| JPH03167134A (ja) | 血栓溶解剤 | |
| JPS62283932A (ja) | 組織プラスミノ−ゲンアクチベ−タの乾燥製剤 | |
| JP2739584B2 (ja) | ウロキナーゼ型プラスミノーゲンアクチベーター乾燥製剤 | |
| JPS60248621A (ja) | 一本鎖組織プラスミノ−ゲンアクチベ−タ−の安定化方法 | |
| JPS6087226A (ja) | プラスミノーゲン・アクチベーター前駆体組成物 | |
| JP2714817B2 (ja) | ウロキナーゼ前駆体の製造方法 | |
| JP2005035921A (ja) | 組織プラスミノーゲン活性化因子含有製剤 | |
| JPH02311424A (ja) | プラスミノーゲン活性化因子含有液状組成物 | |
| JPS60174727A (ja) | 新規なプラスミノ−ゲン・アクチベ−タ−の安定化方法 |